Chen Zihao, Chen Xin, Li Dingchao, Jian Jingang, Yao Chang, Wei Xuedong, Hou Jianquan
Department of Urology, The Fourth Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China.
Department of Urology, The First Affiliated Hospital of Soochow University, No. 899 Pinghai Road, Suzhou, 215006, People's Republic of China.
BMC Urol. 2025 Jan 29;25(1):19. doi: 10.1186/s12894-024-01675-6.
Bacillus Calmette-Guerin (BCG) immunotherapy is the standard adjuvant treatment for high-risk, non-muscle invasive bladder cancer (NMIBC). However, BCG immunotherapy is commonly accompanied by significant lower urinary tract symptoms (LUTS) including symptoms such as urinary urgency, frequency, dysuria and pelvic pain. These symptoms can undermine treatment adherence and clinical outcomes. In this study, the treatments for preventing LUTS after BCG instillations were compared through a systemic review and network meta-analysis (NMA).
Eligible studies were obtained from the PubMed, Web of Science, Embase and Cochrane Library databases. We also searched the references of the included studies. Our protocol followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) checklist. We performed NMA using Review Manager 5.3 and STATA MP 18.0.
The analysis included 6 studies with 556 participants. The results of the NMA revealed that celecoxib and prulifloxacin effectivelty reduce the incidence of LUTS including frequency, urgency and dysuria. Phenazopyridine showed the best performance in improving pelvic pain.
The NMA indicated that medications such as celecoxib, prulifloxacin and phenazopyridine are effective in reducing the incidence of LUTS after BCG immunotherapy of bladder tumors.
卡介苗（BCG）免疫疗法是高危非肌层浸润性膀胱癌（NMIBC）的标准辅助治疗方法。然而，BCG免疫疗法通常会伴随明显的下尿路症状（LUTS），包括尿急、尿频、尿痛和盆腔疼痛等症状。这些症状会影响治疗依从性和临床疗效。在本研究中，通过系统评价和网状Meta分析（NMA）比较了卡介苗灌注后预防LUTS的治疗方法。
从PubMed、Web of Science、Embase和Cochrane图书馆数据库中获取符合条件的研究。我们还检索了纳入研究的参考文献。我们的方案遵循系统评价和Meta分析的首选报告项目（PRISMA）清单。我们使用Review Manager 5.3和STATA MP 18.0进行NMA。
该分析纳入了6项研究，共556名参与者。NMA结果显示，塞来昔布和普卢利沙星能有效降低包括尿频、尿急和尿痛在内的LUTS发生率。非那吡啶在改善盆腔疼痛方面表现最佳。
NMA表明，塞来昔布、普卢利沙星和非那吡啶等药物可有效降低膀胱肿瘤BCG免疫治疗后LUTS的发生率。
